Skip to main content

Spero Therapeutics, Inc.

SPRO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001701108

No open-market purchases or sales by Spero Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $47.5M in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding Spero Therapeutics, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of SPRO: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders7969−10
Shares21.0M19.9M−1.11M (−5.3%)
Value$15.5M$39.7M+$24.2M (+155.8%)

New holders (14)

Institutions that held Spero Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to SPRO in Q3 2022
InstitutionSharesValue% of portfolio
AWM Investment Company, Inc.2,300,400$4.60M0.70%
Anson Funds Management LP1,473,872$2.95M0.57%
Murchinson Ltd.762,700$1.52M0.44%
Bank of Montreal202,300$415.0K0.00%
DAFNA Capital Management LLC125,000$250.0K0.07%
Squarepoint Ops LLC16,423$33.0K0.00%
Jane Street Group, LLC15,496$31.0K0.00%
Weitzel Financial Services, Inc.14,200$28.4K0.02%
Man Group plc11,184$22.0K0.00%
Quantbot Technologies LP2,900$5.00K0.00%
Atlas Capital Advisors LLC727$1.45K0.00%
Crewe Advisors LLC258$1.00K0.00%
China Universal Asset Management Co., Ltd.329$1.00K0.00%
Royal Bank of Canada43$00.00%

Sold out (24)

Institutions that held Spero Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.